Nishadil
Nishadil Ads Nishadil Astrology Nishadil Developers Nishadil Domains Nishadil Drive Nishadil Finance Nishadil Pay Nishadil Weather Nishdil Calendar Rewards
Signup Signin
Washington | 22°C (scattered clouds)
Topic Feed

ObesityDrug

Showing the latest stories and updates for this topic.
Boehringer Ingelheim’s Survodutide Shows Promise in Late‑Stage Obesity Trials

Boehringer Ingelheim’s Survodutide Shows Promise in Late‑Stage Obesity Trials
Eli Lilly’s Next‑Gen Obesity Pill Shows Promise in Tackling Sleep Apnea and More

Eli Lilly’s Next‑Gen Obesity Pill Shows Promise in Tackling Sleep Apnea and More
Eli Lilly’s Next‑Gen Obesity Pill Shows Promise for Sleep Apnea and More

Eli Lilly’s Next‑Gen Obesity Pill Shows Promise for Sleep Apnea and More
Pfizer's Bold Gambit: A Nearly Half-Billion Dollar Bet on China's Obesity Market

Pfizer's Bold Gambit: A Nearly Half-Billion Dollar Bet on China's Obesity Market
Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly
Viking Therapeutics Rockets Skyward: Is Their Obesity Drug the Next Market Game-Changer?

Viking Therapeutics Rockets Skyward: Is Their Obesity Drug the Next Market Game-Changer?
A Collective Sigh of Relief: Eli Lilly Breaks Nine-Day Losing Streak

A Collective Sigh of Relief: Eli Lilly Breaks Nine-Day Losing Streak
The Billion-Dollar Battle for a Breakthrough: Pfizer's Big Bet on Oral Obesity Drugs

The Billion-Dollar Battle for a Breakthrough: Pfizer's Big Bet on Oral Obesity Drugs
The Race for a Breakthrough: Pfizer's Bold Bet on Battling Obesity, Outmaneuvering Novo Nordisk

The Race for a Breakthrough: Pfizer's Bold Bet on Battling Obesity, Outmaneuvering Novo Nordisk
The Billion-Dollar Battle for the Future of Weight Loss: Pfizer Jumps into the Ring

The Billion-Dollar Battle for the Future of Weight Loss: Pfizer Jumps into the Ring
The Weight of Ambition: Pfizer’s Bold Move into the Obesity Race

The Weight of Ambition: Pfizer’s Bold Move into the Obesity Race
The Battle for the Next Blockbuster: Pfizer Steps Up in the Obesity Drug Wars

The Battle for the Next Blockbuster: Pfizer Steps Up in the Obesity Drug Wars
The $11.6 Billion Bet: Pfizer Jumps Headfirst into the Weight Loss Race

The $11.6 Billion Bet: Pfizer Jumps Headfirst into the Weight Loss Race
The Pharmaceutical Thunderdome: Pfizer's Bold Play in the Billion-Dollar Battle for Obesity Drugs

The Pharmaceutical Thunderdome: Pfizer's Bold Play in the Billion-Dollar Battle for Obesity Drugs
The Great Weight-Loss Gambit: Pfizer Jumps into the Billion-Dollar Battle for Obesity Treatment Supremacy

The Great Weight-Loss Gambit: Pfizer Jumps into the Billion-Dollar Battle for Obesity Treatment Supremacy
The Great Weigh-In: Pfizer's Bold Bet in the Billion-Dollar Battle for Obesity Drug Dominance

The Great Weigh-In: Pfizer's Bold Bet in the Billion-Dollar Battle for Obesity Drug Dominance
The Great Weight-Loss Race: Pfizer's Billion-Dollar Gambit to Conquer Obesity

The Great Weight-Loss Race: Pfizer's Billion-Dollar Gambit to Conquer Obesity
A Tsunami of Pills: Eli Lilly's Grand Plan to Conquer the Weight Loss Market

A Tsunami of Pills: Eli Lilly's Grand Plan to Conquer the Weight Loss Market
Cagrisema: Novo Nordisk's Dual-Action Powerhouse Poised to Revolutionize Obesity Treatment

Cagrisema: Novo Nordisk's Dual-Action Powerhouse Poised to Revolutionize Obesity Treatment
Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s

Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s
Novo Nordisk's Strategic Overhaul: 9,000 Job Cuts to Propel Future Dominance

Novo Nordisk's Strategic Overhaul: 9,000 Job Cuts to Propel Future Dominance
Viking Therapeutics' Oral Weight Loss Drug Stumbles: VK2735 Data Leaves Investors Underwhelmed

Viking Therapeutics' Oral Weight Loss Drug Stumbles: VK2735 Data Leaves Investors Underwhelmed
Load more..